Five-year Local Control in a Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy With an Incorporated Boost for Early Stage Breast Cancer

被引:33
|
作者
Freedman, Gary M. [1 ]
Anderson, Penny R. [2 ]
Bleicher, Richard J. [4 ]
Litwin, Samuel [3 ]
Li, Tianyu [3 ]
Swaby, Ramona F. [5 ]
Ma, Chang-Ming Charlie [2 ]
Li, Jinsheng [2 ]
Sigurdson, Elin R. [4 ]
Watkins-Bruner, Deborah [6 ]
Morrow, Monica [7 ]
Goldstein, Lori J. [5 ]
机构
[1] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[2] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Dept Biostat, Philadelphia, PA 19111 USA
[4] Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA
[5] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[6] Emory Univ, Sch Nursing, Atlanta, GA 30322 USA
[7] Mem Sloan Kettering Canc Ctr, Dept Surg Oncol, New York, NY 10021 USA
关键词
Breast boost; Breast cancer; Hypofractionation; IMRT; Radiation therapy; CONSERVING SURGICAL-PROCEDURES; QUALITY-OF-LIFE; RANDOMIZED-TRIAL; RADIOTHERAPY; WOMEN; IRRADIATION; SURGERY; FORM; RT;
D O I
10.1016/j.ijrobp.2012.01.091
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Conventional radiation fractionation of 1.8-2 Gy per day for early stage breast cancer requires daily treatment for 6-7 weeks. We report the 5-year results of a phase II study of intensity modulated radiation therapy (IMRT), hypofractionation, and incorporated boost that shortened treatment time to 4 weeks. Methods and Materials: The study design was phase II with a planned accrual of 75 patients. Eligibility included patients aged >= 18 years, Tis-T2, stage 0-II, and breast conservation. Photon IMRT and an incorporated boost was used, and the whole breast received 2.25 Gy per fraction for a total of 45 Gy, and the tumor bed received 2.8 Gy per fraction for a total of 56 Gy in 20 treatments over 4 weeks. Patients were followed every 6 months for 5 years. Results: Seventy-five patients were treated from December 2003 to November 2005. The median follow-up was 69 months. Median age was 52 years (range, 31-81). Median tumor size was 1.4 cm (range, 0.1-3.5). Eighty percent of tumors were node negative; 93% of patients had negative margins, and 7% of patients had close (>0 and <2 mm) margins; 76% of cancers were invasive ductal type: 15% were ductal carcinoma in situ, 5% were lobular, and 4% were other histology types. Twenty-nine percent of patients 29% had grade 3 carcinoma, and 20% of patients had extensive in situ carcinoma; 11% of patients received chemotherapy, 36% received endocrine therapy, 33% received both, and 20% received neither. There were 3 instances of local recurrence for a 5-year actuarial rate of 2.7%. Conclusions: This 4-week course of hypofractionated radiation with incorporated boost was associated with excellent local control, comparable to historical results of 6-7 weeks of conventional whole-breast fractionation with sequential boost. (C) 2012 Elsevier Inc.
引用
收藏
页码:888 / 893
页数:6
相关论文
共 50 条
  • [41] Phase I trial of preoperative hypofractionated intensity modulated radiation therapy (IMRT) with incorporated boost and oral capecitabine in locally advanced rectal cancer (vol 67, pg 651, 2007)
    Freedman, G. M.
    Meropol, N. J.
    Sigurdson, E. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (01): : 320 - 320
  • [42] A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients
    Vapiwala, Neha
    Wong, J. Karen
    Handorf, Elizabeth
    Paly, Jonathan
    Grewal, Amardeep
    Tendulkar, Rahul
    Godfrey, Devon
    Carpenter, David
    Mendenhall, Nancy P.
    Henderson, Randal H.
    Stish, Bradley J.
    Vargas, Carlos
    Salama, Joseph K.
    Davis, Brian J.
    Horwitz, Eric M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (04): : 1082 - 1089
  • [43] A Phase II Trial of Once Weekly Hypofractionated Breast Irradiation for Early Stage Breast Cancer
    Eldredge-Hindy, Harriet
    Pan, Jianmin
    Rai, Shesh N.
    Reshko, Leonid B.
    Dragun, Anthony
    Riley, Elizabeth C.
    McMasters, Kelly M.
    Ajkay, Nicolas
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (11) : 5880 - 5892
  • [44] A Phase II Trial of Once Weekly Hypofractionated Breast Irradiation for Early Stage Breast Cancer
    Harriet Eldredge-Hindy
    Jianmin Pan
    Shesh N. Rai
    Leonid B. Reshko
    Anthony Dragun
    Elizabeth C. Riley
    Kelly M. McMasters
    Nicolas Ajkay
    Annals of Surgical Oncology, 2021, 28 : 5880 - 5892
  • [45] Hypofractionated Radiation Therapy for Early Stage Breast Cancer: Outcomes, Toxicities, and Cost Analysis
    Min, Christine
    Connolly, Eileen
    Chen, Tiffany
    Jozsef, Gabor
    Formenti, Silvia C.
    BREAST JOURNAL, 2014, 20 (03): : 267 - 273
  • [46] Cosmetic Outcome of Hypofractionated Breast Cancer Intensity Modulated Radiation Therapy: A Preliminary Report of a Prospective Trial
    Abo-Madyan, Y.
    Aldabbas, O.
    Polednik, M.
    Welzel, G.
    Wenz, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S213 - S213
  • [47] Highly hypofractionated intensity-modulated radiation therapy for nonmetastatic prostate cancer with a simultaneous integrated boost to intraprostatic lesions: a planning study
    Ashida, Ryo
    Nakamura, Kiyonao
    Aizawa, Rihito
    Iramina, Hiraku
    Takayama, Kenji
    Nakamura, Mitsuhiro
    Mizowaki, Takashi
    JAPANESE JOURNAL OF RADIOLOGY, 2022, 40 (02) : 210 - 218
  • [48] Highly hypofractionated intensity-modulated radiation therapy for nonmetastatic prostate cancer with a simultaneous integrated boost to intraprostatic lesions: a planning study
    Ryo Ashida
    Kiyonao Nakamura
    Rihito Aizawa
    Hiraku Iramina
    Kenji Takayama
    Mitsuhiro Nakamura
    Takashi Mizowaki
    Japanese Journal of Radiology, 2022, 40 : 210 - 218
  • [49] Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments
    Marta Scorsetti
    Filippo Alongi
    Antonella Fogliata
    Sara Pentimalli
    Pierina Navarria
    Francesca Lobefalo
    Carlos Garcia-Etienne
    Alessandro Clivio
    Luca Cozzi
    Pietro Mancosu
    Giorgia Nicolini
    Eugenio Vanetti
    Marco Eboli
    Carlo Rossetti
    Arianna Rubino
    Andrea Sagona
    Stefano Arcangeli
    Wolfgang Gatzemeier
    Giovanna Masci
    Rosalba Torrisi
    Alberto Testori
    Marco Alloisio
    Armando Santoro
    Corrado Tinterri
    Radiation Oncology, 7
  • [50] Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments
    Scorsetti, Marta
    Alongi, Filippo
    Fogliata, Antonella
    Pentimalli, Sara
    Navarria, Pierina
    Lobefalo, Francesca
    Garcia-Etienne, Carlos
    Clivio, Alessandro
    Cozzi, Luca
    Mancosu, Pietro
    Nicolini, Giorgia
    Vanetti, Eugenio
    Eboli, Marco
    Rossetti, Carlo
    Rubino, Arianna
    Sagona, Andrea
    Arcangeli, Stefano
    Gatzemeier, Wolfgang
    Masci, Giovanna
    Torrisi, Rosalba
    Testori, Alberto
    Alloisio, Marco
    Santoro, Armando
    Tinterri, Corrado
    RADIATION ONCOLOGY, 2012, 7